36 results about "Alveolus pulmonis" patented technology

The invention discloses a lung benefiting pill with 25 ingredients having the function of being homology of medicine and food. The composition of the lung benefiting pill comprises sea buckthorn, radix pseudostellariae, polyporus umbellatus, platycodon grandiflorum, stir-baked rhizoma dioscoreae, milk steamed poria cocos, longan aril, north astragalus, baked perilla seed, baked semen raphani, baked semen brassicae, radix glehniae, radix salviae miltiorrhizae, spina date seed, gecko tails, cordyceps sinensis, almonds, fructus schisandrae, linden honey, salted alisma orientalis, atractylodes macrocephala koidz baked with bran, angelica sinensis, milk steamed polygonatum kingianum, radix ophiopogonis, raw lily and the like. The lung benefiting pill is advantageous to guarantee normal ventilation of alveolus pulmonis and relieves organism anaerobic condition. Due to the fact that the permeability of lung blood capillary is improved, gas exchange is facilitated, and the symptoms of dyspnea and coughing with expectoration are relieved. Weak people with dyspnea and chronic cough generally has the abnormal phenomenon of hemorheology, synchronic treating of phlegm and blood stasis can solve the root cause of sputum and the root cause of blood stasis, bronchospasm can be relieved, discharging of sputum is promoted, cohesive force of red blood cells can be relieved, the blood viscosity is lowered, the hyperviscosity of the weak patients with dyspnea and chronic cough can be relieved, the cardio-pulmonary function of the patients can be improved, and therefore, the lung benefiting pill has good effect on treatment of the patients of this kind.

The invention pertains to the pharmaceutical preparation field, in particular it relates to the application of peptide and protein drug carrier and its preparation method as the drug carrier in the lung administration, according to the invention, the artificial pulmonary surfactant (APS) having drug absorption-promoting and pulmonary protective functions as a lung administered drug carrier, in particular as the carrier of protein and peptide drug to further provides a drug-APS system. The experiment proves that it can reduce alveolus surface tension, increase the lung compliance, stabilize the intra-alveolar pressure, promote the drug absorption administered from the lungs, and decreases the damage to lungs as the carrier of peptide and protein drug.

The invention discloses an endovenous oxygen transporting device and an oxygen transporting method. The oxygen transporting device comprises a vein oxygen catheter which is inserted in a vein, and a control device which is connected to the end, extending out the vein, of the vein oxygen catheter, wherein by virtue of the control device, an oxygen concentration supplied into the vein oxygen catheter can be precisely controlled. Oxygen is transported to the vein by virtue of the vein oxygen catheter which is inserted in the vein, and the oxygen, bypassing alveolus pulmonis having diffusion dysfunction, directly enters blood and oxygenates with hemoglobin, so as to better replace a lung in the case that lung failure occurs or an oxygenating effect cannot be developed temporarily; in comparison with a membrane oxygenator, an oxygen-carrying substitute or a liquid oxygen filling method, the device is simple in structure, convenient to use and capable of preventing in vitro drainage of the blood, so that various possible infections are avoided; and the device is high in blood-carrying-oxygen content and relatively good in stability.

The invention discloses a probiotic composition as well as a preparation and application of the probiotic composition. The probiotic composition comprises VSL#3, lactobacillus rhamnosus M9 and lactobacillus plantarum P-8 which are mixed in an equal ratio of 1:1:1. The probiotic composition is applied to preparation of a drug for treating or preventing pneumonia, particularly pneumonia caused by respiratory syncytial virus (RSV) infection and infantile bronchopneumonia caused by RSV infection. The probiotic composition can relieve change of lung tissue inflammatory pathologic structures causedby RSV infection and inhibit virus infection process of RSV infection, activate TLR3 and RIG-1 signal pathways in alveolar macrophages to promote production of IFN-beta to inhibit expression of lung inflammation factors, and regulate lung florae and intestinal florae to relieve RSV infection.

The invention is based on the finding that Airway Basal Cells (ABCs) play a key role in the pathobiology of various lung diseases. The invention therefore provides approaches for the treatment and prevention of lung diseases such as fibrotic disorders, pre stages of fibrosis, Chronic Obstructive Lung Diseases (COPD) or other lung disorders. Diseases treatable with the means and methods of the invention are characterized by a cellular remodelling in the alveolar compartment of the lung. Furthermore, the invention provides screening approaches to identify compounds suitable for the treatment of lung diseases.

The invention relates to a medical apparatus, in particular to a radiofrequency ablation volume reduction electrode capable of leading out waste gas in the liver. The radiofrequency ablation volume reduction electrode comprises a radiofrequency electrode tip, a temperature measurement resistor and a liver waste gas draw-out assembly. The radiofrequency electrode tip is connected with a radiofrequency transmission hole arranged in an outer pipe to give out a radiofrequency current, and is used for conducting radiofrequency ablation on lesion tissue of alveolus pulmonis. The temperature measurement resistor is connected with a temperature measurement resistor cable and used for collecting the temperature of an ablation area and regulating the temperature released by a radiofrequency electrode. The liver waste gas draw-out assembly comprises a gas draw-out hole and a gas draw-out passageway connected with the gas draw-out hole, and is used for drawing out waste gas in the liver. The radiofrequency ablation volume reduction electrode can conduct radiofrequency ablation treatment on the lesion tissue of the alveolus pulmonis and can meanwhile draw out a large amount of gas detained in the alveolus pulmonis which loses the function, and therefore the aims of reducing the volume of the liver and treating pulmonary emphysema are achieved.

The invention relates to a method for screening early-stage lung tumor in an assisting mode through bronchoalveolar lavage fluid. Prior-art constraints of conventional lung outside sampling specimens and operation sampling lung specimens are broken through, normal saline is poured into the lung of a patient through a fiber bronchoscope and drawn out to form the bronchoalveolar lavage fluid, M2-PK monoclonal antibodies and second M2-PK antibodies are added, and the concentration of M2-PK in the bronchoalveolar lavage fluid is measured with the enzyme-linked immunosorbent assay method and compared with a critical value 18.68 U/ml; as the fiber bronchoscope can go deep into the lung of the patient, the bronchoalveolar lavage fluid is formed in the mode that alveolus pulmonis of the patient is directly washed and comprises alveolus pulmonis secreta, the lesion characteristics of the lung of the patient can be most reflected, the bronchoalveolar lavage fluid serves as an assistant judgment basis of the early-stage lung tumor, screening of the early-stage lung tumor is more accurate, and in addition, operation is not required, trauma is not generated, the method is safer and more reliable, and cost is also low.

The invention discloses application of Baitouweng decoction in preparation of a medicine for treating pneumonia, and belongs to the technical field of biological medicines. The Baitouweng decoction comprises the following raw materials in parts by weight of 2 parts of radix pulsatillae, 3 parts of cortex phellodendri, 3 parts of coptis chinensis and 3 parts of cortex fraxini. The Baitouweng decoction disclosed by the invention can maintain the integrity of alveolar-vascular barrier, relieve pulmonary edema and cell injury, inhibit pneumonia inflammatory response, inhibit cell apoptosis and regulate and control a TLR4/NF-kappa B signal channel, is used for preparing the medicine for treating the pneumonia, and has a remarkable curative effect.

The invention discloses an application of total flavonoids of astragalus in preparing pharmaceutical for preventing and treating acute radiation pneumonitis. The total flavonoids of astragalus contains various medicinal compositions, has prevention and treatment effects on the acute radiation pneumonitis, and can obviously alleviate lung tissue inflammatory lesion, and relieve incrassation and hyperemia of alveolar wall and alveolus pulmonis clearances, and has obvious effects.